company background image
0KFH logo

Revenio Group Oyj LSE:0KFH Stock Report

Last Price

€24.86

Market Cap

€670.2m

7D

-5.0%

1Y

-4.8%

Updated

13 Mar, 2025

Data

Company Financials +

0KFH Stock Overview

Provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally. More details

0KFH fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance2/6
Financial Health6/6
Dividends4/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Revenio Group Oyj Competitors

Price History & Performance

Summary of share price highs, lows and changes for Revenio Group Oyj
Historical stock prices
Current Share Price€24.86
52 Week High€35.74
52 Week Low€23.38
Beta1.44
1 Month Change-16.84%
3 Month Change-7.84%
1 Year Change-4.83%
3 Year Change-46.15%
5 Year Change26.28%
Change since IPO274.10%

Recent News & Updates

Recent updates

Shareholder Returns

0KFHGB Medical EquipmentGB Market
7D-5.0%-5.2%-2.2%
1Y-4.8%-4.8%6.8%

Return vs Industry: 0KFH matched the UK Medical Equipment industry which returned -4.8% over the past year.

Return vs Market: 0KFH underperformed the UK Market which returned 6.8% over the past year.

Price Volatility

Is 0KFH's price volatile compared to industry and market?
0KFH volatility
0KFH Average Weekly Movement5.9%
Medical Equipment Industry Average Movement6.5%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.2%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0KFH has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0KFH's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001241Jouni Toijalawww.reveniogroup.fi

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; and iCare TONOVET an IOP measuring on animal patients by general veterinary practitioners, veterinary ophthalmologists, and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; and DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images.

Revenio Group Oyj Fundamentals Summary

How do Revenio Group Oyj's earnings and revenue compare to its market cap?
0KFH fundamental statistics
Market cap€670.24m
Earnings (TTM)€18.50m
Revenue (TTM)€103.80m

35.7x

P/E Ratio

6.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0KFH income statement (TTM)
Revenue€103.80m
Cost of Revenue€30.60m
Gross Profit€73.20m
Other Expenses€54.70m
Earnings€18.50m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Apr 29, 2025

Earnings per share (EPS)0.70
Gross Margin70.52%
Net Profit Margin17.82%
Debt/Equity Ratio10.3%

How did 0KFH perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

58%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/13 19:31
End of Day Share Price 2025/03/13 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Revenio Group Oyj is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pia Rosqvist-HeinsalmiCarnegie Investment Bank AB
Daniel LepistöDanske Bank
null nullEvli Bank plc